IMNM Stock — Immunome Inc.: Metrics

Market overview

2 metrics

Share price

$27.07

Market cap

$3.07B

Price action

19 metrics

Price change (1W)

-7.9%

Price change (30D)

+17.6%

Price change (3M)

+39.9%

Price change (6M)

+25.6%

Price change (YTD)

+26.0%

Price change (1Y)

+184.6%

Trailing year

Price change (5Y)

+81.2%

52-week high

$29.83

52-week low

$8.99

Change from 52-week high

-9.3%

Change from 52-week low

+201.1%

Annualized volatility

70.1%

Beta

1.7

RSI (14D)

52.8

Price vs SMA 50

+10.8%

Price vs SMA 200

+22.1%

Avg volume (3M)

1.38M

Relative volume

0.5

Average dollar volume

$31.30M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

113.58M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

5.9

reciprocal yield 17.1%

FCF yield

-7.1%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-8.3%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

—

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$270.46M

Net income (TTM)

−$254.32M

Trailing 12 months

Diluted EPS (TTM)

$-2.54

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-32.41

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+30.2%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-48.4%

Return on assets

-45.0%

Debt / equity

—

Current ratio

15.1

EBITDA (TTM)

−$267.69M

Free cash flow (TTM)

−$219.09M

Quick ratio

15.1

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$217.71M

Total assets

$565.38M

Total debt

$500,000

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$208.79M

Capital expenditures (TTM)

$10.29M

R&D (TTM)

$206.23M

SG&A (TTM)

—

Stock compensation (TTM)

$31.39M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

203

13F filer change QoQ

0

Institutional ownership

104.3%

Short interest

3 metrics

Short interest

15.3%

Latest settlement · 14.9 days to cover

Days to cover

14.9d

Short-squeeze score

72 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$15.68M

Insider-sentiment score

67 / 100

Risk flags

1 metrics

Going concern

—

IMNM · Immunome Inc.

IMNM metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search